Tango Therapeutics Q1 2024 net loss $37.9M ($0.35/sh); cash $343.6M funds into late 2026

Tango Therapeutics, Inc.

2024-Q1 EPS reported -$0.35 revenue$6,471,000

Net loss of $37.9M, or $0.35 per share, vs $28.0M ($0.32) in Q1 2023.
Cash, equivalents and marketable securities of $343.6M as of March 31, 2024.
R&D expense rose to $38.1M from $28.0M due to clinical program advancement.
Dose expansion initiated for TNG908 (PRMT5 inhibitor) in MTAP-deleted tumors.
PRMT5 clinical data update expected in 2H 2024; TNG462 expansion expected Q2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Tango Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: revenue $6.5 million, net income $37.9 million, EPS $0.35 per share.

Period: the first quarter ended March 31, 2024
Revenue: $6.5 million
Net income: $37.9 million
EPS: $0.35 per share
Result: reported results

Exact text from the filing

held $343.6 million in cash, cash equivalents and marketable securities, which the Company expects to be sufficient to fund operations into late 2026. Collaboration revenue was $6.5 million for the three months ended March 31, 2024, compared to $5.8 million for the same period in 2023. Research costs incurred under the collaboration were similar during each of the

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Tango Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-055062

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.